IMPACT BIOMEDICAL INC. (IBO) Form 8-K — Nov 18, 2026
Impact BioMedical completed its business combination with Zoar Limited on November 17, 2026, with Impact surviving the merger as a wholly-owned subsidiary of Zoar (PubCo). IBO holders received 8,640,000 PubCo ordinary shares after a 1-for-12.62 reverse split, representing only about 4.80% of PubCo. Control shifted decisively: Zoar shareholder Kanans Visvanats received 167,976,000 shares, or approximately 94.02% of PubCo, with no cash consideration paid. Impact's entire board, CFO, and COO resigned, and a new PubCo board and executive team led by Visvanats was appointed.
Key figures
- Dss shares
- 228000
- New ticker
- ZOAR
- Bmi capital shares
- 1800000
- Bmi capital percent
- 1.00%
- Reverse split ratio
- 1-for-12.62
- Merger completion date
- 2026-11-17
- Zoar shareholder percent
- 94.02%
- Shares to zoar shareholder
- 167976000
- Pubco shares to ibo holders
- 8640000
- Ibo holders percent of pubco
- 4.80%
- Compensation shares to heuszel
- 22000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.